HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment
Impact Trial conducted at 157 sites in England (Oct 2017 to July 2020) found. PrEP need was higher than initially estimated by expert stakeholder group & high proportion of follow-up time protected by PrEP suggests need for protection persisted for most participants during trial.
Source:
The Lancet HIV
SPS commentary:
Analysis (n=21,356 of 24,268 enrolled before Feb 2020 of which 20,403 [95·5%] were MSM) noted uptake of PrEP was 21 292 (57·1%) of 37 289. A total of 18,400 trial participants had at least one post-enrolment visit and a median of 361 days of follow-up and 14 039 (75·9%) of these had enough PrEP prescribed to provide protection for 75% of their follow-up time.
UKHSA press release points out the study was critical in informing routine commissioning of HIV PrEP which has been in place since October 2020. Findings from this study will now support the ongoing delivery of the government’s HIV Action Plan to help achieve the goal of zero HIV transmissions by 2030.